Akumin — Q2 2023 Earnings Presentation
17 slides from Akumin's earnings presentation, Aug 10, 2023
Slide 1: 2023 Second Quarter Results
Akumin Inc. 2023 Second Quarter Results August 10, 2023 Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forward-Looking Statements This presentation may contain forward-looking information or forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-looki
Slide 3: Q2 2023 Performance Highlights
Same Store Volumes trended positively across the platform: MRI: +3.1% PET/CT: +16.5% Oncology Patient Starts: +3.4% Q2 2023 Performance Revenue of $184.8M, down (3.8%) vs. Q2 2022. Highlights Adjusted EBITDA1 of $26.5M, down (31%) vs. Q2 2022. Adjusted EBITDA margin1 of 14.4%, down from
Slide 4: Operational Update
Operational Update Radiology revenues: ‒ Our Q2 Radiology division revenues were down $4.6M YoY which was attributable to a number of factors including: • the ongoing closure of our Port Charlotte facility due to delays in obtaining necessary permits for renovations; and • delays in mobile equipme
Slide 5: Current Outlook
Current Outlook Radiology: ‒ We expect these issues to persist in varying degrees for the remainder of 2023 and have also factored in some additional equipment delivery delays into our outlook, including our Capex budget. ‒ We are taking steps to alleviate the impact of these challenges, including
Slide 6: Strategic Initiatives
Strategic Initiatives Integration synergies: ‒ Given the operational challenges we experienced in our core businesses in Q2, the implementation of our planned synergy initiatives has been delayed. ‒ As a result, we do not anticipate any material financial benefit from the previously-announced $25M
Slide 7: Formation of a Special Committee
Formation of a Special Committee Special Committee of the Board ‒ The Board of Directors has formed a Special Committee to explore strategic initiatives related to our capital structure. ‒ Recall that interest on our subordinated debt, held by our partner and sponsor Stonepeak, has been Paid-in-Ki
Slide 8: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities Service Lines (% of Revenue) 1 Radiology Procedure Mix Diversification of revenue (% of Revenue) between Radiology and Oncology divisions 20% Akumin provides a full suite of radiology and oncology services 53% with a focus on high-growth 27% and high-value modali
Slide 9: Diverse Payor Mix
Diverse Payor Mix TTM Q2’23 Payor Mix1 % of Revenue of the company’s overall ~95% revenue is derived from outpatient procedures 50% 50% of revenue is received of revenue is received via third party and via health systems government payors, and hospitals, of which and reimbursed at virtually all is f
Slide 10: Volume Trends
Volume Trends MRI, #K procedures PET/CT, #K procedures Oncology, #K patient starts 36.7 221.4 35.8 2.6 219.8 2.6 2.6 216.4 216.9 33.4 33.7 2.5 Q3'22 Q4'22 Q1'23 Q2'23 Q3'22 Q4'22 Q1'23 Q2'23 Q3'22 Q4'22 Q1'23 Q2'23 Same Store Volume Growth1,2, % growth YoY MRI (procedures) PET/CT (procedures) Oncolo
Slide 11: Segment Financial Performance
Segment Financial Performance Revenues ($ in M) Adjusted EBITDA1 and Margin (M) Oncology Radiology 50.0 45.0 19.9% 20.2% 19.6% 20.0% $192.1 $186.6 $184.6 $187.6 $184.8 40.0 17.7% $31.3 $31.5 $31.1 $30.2 $28.5 $38.2 $37.4 35.0 $36.5 $33.1 14.4% 30.0 $160.9 $155.1 $153.6 $157.4 $156.3 25.0 $26.5 20.0
Slide 12: Segment Financial Performance
Segment Financial Performance Annual Pro Forma1 Revenue (M) Adj. EBITDA2 and Margin Pro Forma1 (M) Oncology Radiology Overall margin EBITDA $727 $750 $744 20.1% 19.2% $125 $122 18.0% $132 $146 $144 $134 $595 $625 $622 2021 2022 LTM Q2’23 2021 2022 LTM Q2’23 Source: Company financial reports. 1. Pro
Slide 13: Free Cash Flows (YTD Q2 2023)
Free Cash Flows (YTD Q2 2023) Free Cash Flow (YTD Q2 2023) (M) Increase Decrease AEBITDA Cash Interest Cash Minority Finance Working Cash Capex Other YTD Cash Before MI Interest Lease & LT Capital payments Nonrecurring 1 Flow Debt Change Payments 1. “Other Nonrecurring” comprise primarily of 3rd Par
Slide 14: Revised 2023 Guidance
We now expect 2023 results as follows: Revenue range $740M-$750M Adjusted EBITDA1 range $120M-$130M Total CAPEX spend of ~$40-$50M: Revised 2023 ‒ ~$10-$20M earmarked for growth capex for new customers and new Guidance sites ‒ Total capex to be funded with approx. 20% in cash and the balance f
Slide 15: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation Adjusted EBITDA1 $125.0 for Growth Total Secured Debt $913.8 Akumin’s capital structure is comprised of a diverse set of capital providers Less: Cash 38.0 including traditional banks, bondholders and Stonepeak as debt and equity Net Secured Debt $875.8 stakehol
Slide 16: Thank you!
Thank you! Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 17: Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA
Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA Three-month period ended S ix-month period ended (in thousands) June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Net (Loss) $ (94,279) $ (26,079) $ (123,469) $ (52,511) Interest expense 31,164 29,290 61,861 57,971 Income tax expense (b